文献速递泌尿男性生殖肿瘤

METEOR III期试验年龄亚组分析:卡博替尼对比依维莫司在晚期肾细胞癌中的疗效与安全性

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
PubMed 文献 · Eur J Cancer · 2019-12-27

基于METEOR III期试验的回顾性年龄亚组分析,将晚期肾细胞癌患者按年龄分为<65岁、65-74岁和≥75岁三组。结果显示卡博替尼在全部年龄亚组中均较依维莫司改善无进展生存期、总生存期和客观缓解率,且年龄作为分类或连续变量对PFS或OS无显著影响。老年患者接受卡博替尼时疲劳、高血压和低钠血症更常见,因不良事件导致的剂量调整和停药在老年患者中更频繁。

要点

  • 卡博替尼在<65岁、65-74岁和≥75岁亚组中均较依维莫司改善PFS、OS和ORR。
  • 年龄作为分类或连续变量对PFS或OS无显著影响。
  • 老年患者使用卡博替尼时疲劳、高血压和低钠血症更常见,需主动剂量调整和支持治疗。

核心结论

  • 卡博替尼在经治晚期肾细胞癌患者中较依维莫司改善PFS、OS和ORR,且不受年龄组影响,支持在所有年龄组中使用。

研究设计与样本

  • METEOR III期试验(NCT01865747)的回顾性年龄亚组分析,按年龄分为<65岁(n=394)、65-74岁(n=201)和≥75岁(n=63)三组。

主要发现

  • PFS风险比在<65岁、65-74岁和≥75岁组分别为0.53(95%CI 0.41-0.68)、0.53(95%CI 0.37-0.77)和0.38(95%CI 0.18-0.79)。
  • OS风险比在<65岁、65-74岁和≥75岁组分别为0.72(95%CI 0.54-0.95)、0.66(95%CI 0.44-0.99)和0.57(95%CI 0.28-1.14)。
  • 卡博替尼对比依维莫司的ORR在<65岁、65-74岁和≥75岁组分别为15% vs 5%、21% vs 2%和19% vs 0%。
  • 年龄作为分类或连续变量对PFS或OS无显著影响。
  • III/IV级不良事件在各亚组间总体一致,但老年患者接受卡博替尼时疲劳、高血压和低钠血症更常见。

临床怎么用

  • 卡博替尼可考虑用于所有年龄组的经治晚期肾细胞癌患者,老年患者需主动进行剂量调整和支持治疗以减轻不良事件。

局限性

  • 回顾性亚组分析,样本量随年龄增长而减少,≥75岁组仅63例,可能影响统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cabozantinib improved progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) compared with everolimus in patients with advanced renal cell carcinoma (RCC) after prior antiangiogenic therapy in the phase III METEOR trial (NCT01865747). Limited data are available on the use of targeted therapies in older patients with advanced RCC. METHODS: Efficacy and safety in METEOR were retrospectively analysed for three age subgroups: <65 (n = 394), 65-74 (n = 201) and ≥75 years (n = 63). RESULTS: PFS, OS and ORR were improved with cabozantinib compared with everolimus in all age subgroups. The PFS hazard ratios (HRs) were 0.53 (95% confidence interval [CI]: 0.41-0.68), 0.53 (95% CI: 0.37-0.77) and 0.38 (95% CI: 0.18-0.79) for <65, 65-74 and ≥75 years, respectively, and the OS HRs were 0.72 (95% CI: 0.54-0.95), 0.66 (95% CI: 0.44-0.99) and 0.57 (95% CI: 0.28-1.14). The ORR for cabozantinib versus everolimus was 15% vs 5%, 21% vs 2% and 19% vs 0%, respectively. No significant differences were observed in PFS or OS with age as a categorical or continuous variable. Grade III/IV adverse events (AEs) were generally consistent across subgroups, although fatigue, hypertension and hyponatraemia occurred more frequently in older patients treated with cabozantinib. Dose reductions to manage AEs were more frequent in patients receiving cabozantinib than in those receiving everolimus. Dose reductions and treatment discontinuation due to AEs were more frequent in older patients in both treatment groups. CONCLUSIONS: Cabozantinib improved PFS, OS and ORR compared with everolimus in previously treated patients with advanced RCC, irrespective of age group, supporting use in all age categories. Proactive dose modification and supportive care may help to mitigate AEs in older patients while maintaining efficacy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Donskov F, Motzer RJ, Voog E, et al. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2019. PMID: 31887537. doi:10.1016/j.ejca.2019.10.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。